|
||
|
|
|
|
Meet the Professor Mike Rogers
Enormous progress has been made over the last few years in understanding how bisphosphonate drugs (BPs) act at the molecular level to inhibit bone resorption. Recent studies have illustrated how BPs are internalised by osteoclasts, helping to explain their selective action on osteoclasts, while the elucidation of the x-ray crystal structure of nitrogen-containing BPs bound to their target enzyme (FPP synthase) has provided new insights into the structure-activity relationships of these compounds and hence why BPs differ in their potency. This session will summarise these findings and discuss current concepts of how inhibition of FPP synthase affects protein prenylation and signalling pathways in osteoclasts, how inhibition of this enzyme can cause an acute phase reaction in some patients, and to what extent BPs might also affect cell types other than osteoclasts in vivo, such as tumour cells. The session will be interactive, addressing questions from the audience and developing discussion with participants. The session will be of interest to anyone with an interest in clinical and pre-clinical effects of bisphosphonate drugs. |
||||||||||||||||
|
|
||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
